CMMB
NASDAQChemomab Therapeutics Ltd.
News · 26 weeks20-25%
2025-12-142026-06-07
Mix1890d
- Insider10(56%)
- SEC Filings6(33%)
- Other2(11%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Melincoff Gwen A3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- INSIDERChief Executive Officer Mor George Adi disposed of 50,462 units of American Depositary Shares, decreasing direct ownership by 87% to 18,750 units (SEC Form 4)4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- PRChemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update—New Clinical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD— —Company Continues to Advance Multiple Partnering Options for Nebokitug— TEL AVIV, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2026, and provided a corporate update. "In the first q
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- INSIDERSEC Form 3 filed by new insider Mor George Adi3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Darvish Nissim3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cohen Neil Harris3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Moses Alan Charles3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fatal Sigal3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lawler John3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Quigley Jill M.3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- INSIDERSEC Form 3 filed by new insider Nicaise Claude3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
- SECSEC Form 20-F filed by Chemomab Therapeutics Ltd.20-F - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Chemomab Therapeutics Ltd.SCHEDULE 13G/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)
- PRChemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences ConferenceTEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The corporate presentation will be webcast live and will be available at the investor relations section of the Chemomab website for 90 days. Oppenheimer 36th Annual Healthcare Life Sciences Confere
- PRChemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology—New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a Phase 3 Registration Trial— TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the results of its Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis (PSC) were published in the current issue of the American Journal of Gastroenterology.1 The study showed that nebokitug was generally safe and w
- PRChemomab to Participate in Oppenheimer's Movers in Rare Disease SummitTEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that co-founder and CEO Adi Mor, PhD, will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 11, 2025, at the Sofitel Hotel in New York City. The invitation-only Rare Disease Summit will feature a day of panels, presentations and 1-on-1 investor meetings with companies working in the rare disease space. Dr. Mor will present a corporate overview and will be available for one-on-one meetings with registered attendee
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
- PRChemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data Provides Insights on Nebokitug's Direct Macrophage-Mediated Mechanisms that Are Key to PSC Disease Progression— —All Three Presentations Have Been Designated as Posters of Distinction— TEL AVIV, Israel and WASHINGTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that abstracts that highlight new clinical data from t
- SECSEC Form 6-K filed by Chemomab Therapeutics Ltd.6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)
CMMB FAQ
7 questionsWhat does Chemomab Therapeutics Ltd. do?
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.Where does CMMB stock trade?
Chemomab Therapeutics Ltd. (CMMB) is listed on NASDAQ.What sector and industry is CMMB in?
Chemomab Therapeutics Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Chemomab Therapeutics Ltd. go public?
Chemomab Therapeutics Ltd. (CMMB) completed its IPO in 2019.What are analysts saying about CMMB?
Chemomab Therapeutics Ltd. has had 5 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $400.00 price target on 2024-05-13.What companies are similar to CMMB?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CMMB side-by-side with any of them on Quantisnow.How can I track CMMB on Quantisnow?
Quantisnow aggregates Chemomab Therapeutics Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CMMB to receive live email and push alerts on every new disclosure.